LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website at ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. Abo ...

LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 2:00 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com. A replay of the webcast will be available fo ...

LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 2:00 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com. A replay of the webcast will be available fo ...

Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors [2] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [2] - The company has multiple ADCs in ongoing clinical and preclinical development [2] Upcoming Events - Ameet Mallik, CEO of ADC Therapeutics, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024, at 1:35 p.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for approximately 30 days [1]

Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors [2] - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [3] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [2] - The company has multiple ADCs in ongoing clinical and preclinical development [2] Upcoming Events - Ameet Mallik, CEO of ADC Therapeutics, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024, at 1:35 p.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for approximately 30 days [1]

ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - CEO Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - CMO Patrick van Berkel - Chief Scientific Officer Jose Carmona - CFO Conference Call Participants Yun Zhong - Jefferies Michael Schmidt - Guggenheim Securities Unidentified Analyst - RBC Capital Markets Brian Cheng - J.P. Morgan Chase Operator Good day ...

1Q 2024 Earnings Call May 6, 2024 Agenda Ameet Mallik 01 ...

Company Performance - ADC Therapeutics reported a quarterly loss of $0.56 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.74 per share a year ago [1] - The company's revenues for the quarter ended March 2024 were $18.05 million, missing the Zacks Consensus Estimate by 0.75% and down from $18.99 million year-over-year [1] - Over the last four quarters, ADC Therapeutics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [1] Stock Movement and Outlook - ADC Therapeutics shares have increased approximately 195.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.5% [2] - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call [2] Earnings Estimates and Industry Context - The current consensus EPS estimate for the upcoming quarter is -$0.58 on revenues of $20.01 million, and for the current fiscal year, it is -$2.20 on revenues of $83.22 million [4] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - ThermoGenesis Holdings, Inc., another company in the same industry, is expected to report quarterly earnings of $0.01 per share, reflecting a year-over-year change of +100.3% [5]

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price). The gross proceeds from the o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Switzerland Not Applicable ( ...